Latest news with #Trisomy21
Business Wire
27-05-2025
- Business
- Business Wire
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors. Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors. Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame. About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
27-05-2025
- Business
- Yahoo
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors. Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors. Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame. About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB1-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4Ticker: AELISB Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements. View source version on Contacts AELIS FARMA Pier Vincenzo PiazzaChief Executive Officercontact@ NewCap Dusan Oresansky / Aurélie ManavarereInvestor Relationsaelis@ +33 1 44 71 94 92 NewCap Arthur RouilléMedia Relationsaelis@ +33 1 44 71 00 15
Time Business News
23-05-2025
- Health
- Time Business News
Planning for Your Baby's Health: Non-Invasive Prenatal Screening and Stem Cell Collection Insights
Parenthood is a memorable journey filled with hopes and dreams for your baby's future. Early pregnancy health checks for your baby are now possible with the latest medical innovations, and even protect their future with special cells collected at birth. Two essential services many parents are choosing today are: Non-invasive prenatal screening (NIPS) — to check your baby's health early. — to check your baby's health early. Stem cell collection — to preserve life-saving cells from your baby's umbilical cord. Whether you're doing a simple prenatal test or planning to collect stem cells, First Stem Cell and Genomics Laboratory makes the process smooth, clear, and supportive. Non-invasive prenatal screening is a safe and simple test that helps determine whether your baby might have certain genetic conditions. NIPS helps give you peace of mind and more time to make decisions, especially if further testing or support is needed. Here's what makes NIPS a considerable decision by parents: It's done with a simple blood test from the mother — no risk to the baby. You can take the test as early as 10 weeks into pregnancy. It looks for common chromosome conditions like: Down syndrome (Trisomy 21) Trisomy 18 and Trisomy 13 Some sex chromosome disorders It provides accurate and early results, usually within 5 to 10 days. NIPS benefits parents who want more information about their baby's health without the stress of invasive procedures. Many expecting parents now prefer NIPS because it's: Risk-Free – No risk of needles near the baby – No risk of needles near the baby Easy Process – Just a small blood draw from the mother – Just a small blood draw from the mother Fast Turnaround – Quick results to ease your worries – Quick results to ease your worries High-Accuracy – Highly accurate for detecting certain conditions – Highly accurate for detecting certain conditions Doctor-recommended – Trusted by medical experts around the world Stem cell collection is a special process that happens at birth. It involves collecting blood samples from the umbilical cord containing powerful stem cells. These cells are like building blocks, as they can grow into different types of healthy blood and immune cells. Doctors already use them to treat many serious illnesses. Conditions treated with stem cells include: Leukemia and some other cancers Conditions affecting the blood, including sickle cell anemia and thalassemia Immune system disorders Research is ongoing for conditions like cerebral palsy and diabetes Saving stem cells is a way of planning and giving your family more medical options in case of future illness. Here's why many families are choosing stem cell collection: It's a one-time chance — the umbilical cord can only be collected at birth. The process is safe and painless for both baby and mother. These stem cells could be used in future treatments. They're a valuable medical resource, just like a health safety net for your child. Choosing where to do these tests is just as crucial as deciding. FSG is a trusted medical lab that offers non-invasive prenatal screening and stem cell collection services. Accurate testing with the latest medical technology Fast results that you can count on A friendly support team to guide you through every step Safe and professional collection of stem cells at birth Help with insurance and flexible, affordable plans Access to genetic counseling if you have questions about your results A trusted and precise test to learn about your baby's health during the first weeks of pregnancy. Talk to your doctor about getting NIPS. Visit a clinic or lab to give a blood sample. Wait 5–10 days for your results. Review the results with your doctor to understand the next steps. Sign up with FSG before your delivery. A trained professional collects the umbilical cord blood when your baby is born. The stem cells are safely stored in a secure facility. You'll receive confirmation that your child's stem cells are preserved for future use. Your baby's health begins before birth, and accurate insights give you more confidence to protect it. With non-invasive prenatal screening, you get valuable information early in your pregnancy. By choosing stem cell collection, you create a health resource that could be life-saving one day. Contact FSG today to learn more about our services, book your screening, or register for stem cell collection. With the support of a lab you can rely on, give your baby the healthiest possible start in life. TIME BUSINESS NEWS
Gulf News
01-05-2025
- Business
- Gulf News
Cafe run by Down Syndrome staff opens in Dubai, brewed with love and inclusion
A heartwarming new café in Dubai is turning heads—not just for its coffee and cakes, but for its inclusive mission. 21 Cafe, which opened its doors at Al Ghurair Centre in Deira on April 25, is mostly staffed by people of determination (Down Syndrome) , working proudly as support employees alongside professional baristas. The café is the brainchild of a parent, Raghu Raman Dhandapani, whose own 25-year-old son has Down Syndrome. For him, this is more than a business—it's a deeply personal attempt to build a world where people of determination are not sidelined, but included in everyday spaces and empowered to lead functional, independent lives. 'We want to show that individuals with Down Syndrome are capable of much more than society expects. They can lead fully functional lives if given the right support,' said John Mathew Paul, the café's manager, who shared the vision behind this pioneering concept with Gulf News. At present, four young adults with Down Syndrome support the baristas by serving coffee, cakes, and offering warm customer interactions. But this is only the beginning. The founders plan to expand the initiative into a chain of cafés across Dubai malls and airports. The café's name— 21 Cafe —holds deep significance. It references Trisomy 21, the extra 21st chromosome that characterises Down Syndrome.
Arabian Business
01-05-2025
- Health
- Arabian Business
Dubai's Al Ghurair Centre opens new 21 Café run by staff with Down Syndrome
Al Ghurair Centre, the Middle East's first modern shopping mall, has unveiled 21 Café, Dubai's first food and beverage establishment operated entirely by staff with Down Syndrome. The initiative comes as part of Dubai's ongoing commitment to support people of determination, ensuring inclusivity across all sectors of society. A post shared by Al Ghurair Centre (@alghuraircentre) Down Syndrome, which affects approximately one in 800 births globally, has a higher prevalence in the Middle East at 2.2 per 1,000 live births, according to figures from the Centre for Arab Genomic Studies. Beyond medical challenges, individuals with this genetic condition often encounter significant social barriers. The café's name references Trisomy 21, the medical term describing the extra copy of chromosome 21 that causes Down Syndrome. Raghu Raman, Owner and Managing Director of 21 Café, established the venue after being inspired by his son's experiences. The establishment, located on the second floor of Al Ghurair Centre, represents a significant development during the UAE's designated Year of Community, showcasing the emirate's dedication to accessibility and inclusion. Medical experts note that whilst those with Down Syndrome face developmental challenges, supportive environments can facilitate significant achievements. As Dubai
